[{"address1": "455 Mission Bay Boulevard South", "city": "San Francisco", "state": "CA", "zip": "94158", "country": "United States", "phone": "415 482 5300", "fax": "415 339 5300", "website": "https://www.nektar.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.", "fullTimeEmployees": 61, "companyOfficers": [{"maxAge": 1, "name": "Mr. Howard W. Robin", "age": 71, "title": "CEO, President & Director", "yearBorn": 1953, "fiscalYear": 2024, "totalPay": 2166571, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sandra A. Gardiner", "age": 58, "title": "CFO and Principal Financial & Accounting Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 460850, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark A. Wilson J.D.", "age": 52, "title": "Senior VP, Chief Legal Officer & Secretary", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 898297, "exercisedValue": 0, "unexercisedValue": 46583}, {"maxAge": 1, "name": "Dr. Jonathan  Zalevsky Ph.D.", "age": 49, "title": "Senior VP and Chief Research & Development Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 1151200, "exercisedValue": 0, "unexercisedValue": 35833}, {"maxAge": 1, "name": "Mr. Jason  Barnard", "title": "Chief Accounting Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Bacci", "title": "Chief People Officer and Head of Quality & Facilities", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Ruddock", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mary  Tagliaferri L.Ac., M.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ken  Franke Ph.D.", "title": "Senior Vice President of Biologics Process Development & Manufacturing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Charleen  Jue", "title": "Senior Vice President of Clinical Development Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 2, "overallRisk": 5, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://ir.nektar.com/", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 63.64, "open": 63.11, "dayLow": 59.2349, "dayHigh": 64.95, "regularMarketPreviousClose": 63.64, "regularMarketOpen": 63.11, "regularMarketDayLow": 59.2349, "regularMarketDayHigh": 64.95, "payoutRatio": 0.0, "beta": 1.197, "forwardPE": -78.05195, "volume": 1353495, "regularMarketVolume": 1353495, "averageVolume": 996365, "averageVolume10days": 1053690, "averageDailyVolume10Day": 1053690, "bid": 58.0, "ask": 68.45, "bidSize": 2, "askSize": 1, "marketCap": 1143016192, "fiftyTwoWeekLow": 6.45, "fiftyTwoWeekHigh": 65.79, "allTimeHigh": 1670.4, "allTimeLow": 6.15, "priceToSalesTrailing12Months": 15.253639, "fiftyDayAverage": 48.1508, "twoHundredDayAverage": 22.9456, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1143842176, "profitMargins": -1.63172, "floatShares": 17594272, "sharesOutstanding": 19018573, "sharesShort": 1731971, "sharesShortPriorMonth": 1607714, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0911, "heldPercentInsiders": 0.00709, "heldPercentInstitutions": 0.48734, "shortRatio": 1.69, "shortPercentOfFloat": 0.0928, "impliedSharesOutstanding": 20138802, "bookValue": -1.944, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -122271000, "trailingEps": -8.64, "forwardEps": -0.77, "lastSplitFactor": "1:15", "lastSplitDate": 1749427200, "enterpriseToRevenue": 15.265, "enterpriseToEbitda": -8.339, "52WeekChange": 1.9460785, "SandP52WeekChange": 0.16625166, "quoteType": "EQUITY", "currentPrice": 60.1, "targetHighPrice": 120.0, "targetLowPrice": 30.0, "targetMeanPrice": 93.85714, "targetMedianPrice": 100.0, "recommendationMean": 1.875, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 175903008, "totalCashPerShare": 9.249, "ebitda": -137164992, "totalDebt": 176728992, "quickRatio": 2.483, "currentRatio": 2.613, "totalRevenue": 74934000, "revenuePerShare": 5.344, "returnOnAssets": -0.31570998, "returnOnEquity": -4.40799, "grossProfits": 62522000, "freeCashflow": -58484376, "operatingCashflow": -184910000, "revenueGrowth": -0.524, "grossMargins": 0.83435994, "ebitdaMargins": -1.8304801, "operatingMargins": -3.20206, "financialCurrency": "USD", "symbol": "NKTR", "language": "en-US", "region": "US", "typeDisp": "Equity", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 767971800000, "postMarketChangePercent": 0.099835895, "postMarketPrice": 60.16, "postMarketChange": 0.060001373, "regularMarketChange": -3.54, "regularMarketDayRange": "59.2349 - 64.95", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 996365, "fiftyTwoWeekLowChange": 53.649998, "fiftyTwoWeekLowChangePercent": 8.317829, "fiftyTwoWeekRange": "6.45 - 65.79", "fiftyTwoWeekHighChange": -5.6900024, "fiftyTwoWeekHighChangePercent": -0.086487345, "fiftyTwoWeekChangePercent": 194.60785, "earningsTimestamp": 1754596800, "earningsTimestampStart": 1762459200, "earningsTimestampEnd": 1762459200, "earningsCallTimestampStart": 1754600400, "earningsCallTimestampEnd": 1754600400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -8.64, "epsForward": -0.77, "epsCurrentYear": -10.35479, "shortName": "Nektar Therapeutics", "longName": "Nektar Therapeutics", "priceEpsCurrentYear": -5.804077, "fiftyDayAverageChange": 11.9492, "fiftyDayAverageChangePercent": 0.24816203, "twoHundredDayAverageChange": 37.154396, "twoHundredDayAverageChangePercent": 1.6192384, "priceToBook": -30.915636, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.9 - Buy", "cryptoTradeable": false, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1761350384, "regularMarketTime": 1761336001, "exchange": "NCM", "messageBoardId": "finmb_29929", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -5.56254, "regularMarketPrice": 60.1, "trailingPegRatio": null, "__fetch_time": "2025-10-25"}]